巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Histogen

    HSTO
    0.181
    0.010
    5.10%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Histogen - 延遲價格・最後更新於 26/05 6:08
    最高位
    0.185
    最低位
    0.179
    開市價
    --
    前收市價
    0.172
    成交量(千)
    20.91
    成交額(百萬)
    0.04
    買入
    0.178
    賣出
    0.183
    每手股數
    --
    市值(百萬)
    9.05
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    1.230 - 0.150
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Histogen
    證券代碼
    HSTO.US
    所屬板塊
    Biotechnology
    公司業務
    Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
    發行量
    49950212
    公司總部
    10655 Sorrento Valley Road, Suite 200
    公司網址
    https://www.histogen.com
    公司電話
    +1 858 526-3100
    暫無內容

    關於

    Histogen(HSTO.US)所屬的行業板塊為Biotechnology。
    Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
    詳細公司背景可參考: https://www.histogen.com